ClinicalTrials.Veeva

Menu

A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin

Shanghai Jiao Tong University logo

Shanghai Jiao Tong University

Status

Unknown

Conditions

Lymphoma

Treatments

Drug: liposomal doxorubicin

Study type

Observational

Funder types

Other

Identifiers

NCT04069845
Realipo-01

Details and patient eligibility

About

This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.

Enrollment

2,000 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • histologically confirmed lymphoma
  • 18-80 years
  • ECOG<= 2
  • newly diagnosed lymphoma
  • liposomal doxorubicin is planned in the treatment
  • normal lung function
  • no history or malignancy
  • informed consented

Exclusion criteria

  • history of malignancy, now in the treatment
  • pregnant
  • serious infection
  • other uncontrollable conditions judged by the investigator

Trial design

2,000 participants in 1 patient group

liposomal doxorubicin treatment
Description:
intravenous liposomal doxorubicin
Treatment:
Drug: liposomal doxorubicin

Trial contacts and locations

1

Loading...

Central trial contact

WL Z

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems